drugset / Trial / NCT04800692
The Effects of ATLAS Therapy on Nitric Oxide Bioavailability in Patients With Intermittent Claudication
Non-randomizedParallel-groupOpen-labelOther
Summary
This study will focus on people with claudication from peripheral arterial disease. The investigators are researching whether a multicomponent therapeutic can increase the production of Nitric Oxide in the blood and whether that leads to an improvement in pain free walking distance and overall physical activity.
Timeline
- Start
- 2021-06-15
- Primary completion
- 2027-07
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | L-Ascorbate | Unknown | 3300 mg | — |
| Subject | L-arginine | Small molecule | 3400 mg | — |
| Subject | sapropterin | Unknown | 10 mg/kg | — |
| Subject | sapropterin | Unknown | 20 mg/kg | — |